Stock & Company Details
Arrowhead Pharmaceuticals Inc. $ARWR
Price:
N/A
N/A
141M
$8.6B
52 Week High:
N/A
10 Day Average Volume:
N/A
-27.11
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
ARWR technical indicators
Latest Arrowhead Pharmaceuticals Inc. (ARWR) indicator readings as of 2026-10-09.
ARWR's 14-day RSI is 32.8, in neutral territory. At $62.75 it is trading 13.3% below its 200-day moving average of $72.37, and below its 50-day average of $78.38. Price sits in the middle of its Bollinger Bands ($57.59 to $75.00). ADX reads 34.8, indicating a trending market.
ARWR backtested strategy results
How 4 rule-based strategies performed on Arrowhead Pharmaceuticals Inc. (ARWR) over recent history, last backtested 2026-10-07. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +197.9% | 41% | 17 | -36.0% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | -5.7% | 32% | 31 | -87.7% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | -23.8% | 33% | 30 | -82.5% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +127.1% | 59% | 32 | -40.3% |
Overview
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Finance Bot
Ask your questions
Start by typing a question below.
